The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e164   doi:10.58347/tml.2024.1713g
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of Capvaxive, a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.
 Select a term to see related articles  PCV13   pneumococcal vaccine   PPSV23   vaccines 

View Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old

Download PDF: US English

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article